Welcome to our dedicated page for Nuvectis Pharma news (Ticker: NVCT), a resource for investors and traders seeking the latest updates and insights on Nuvectis Pharma stock.
Nuvectis Pharma, Inc. reports developments as a clinical-stage biopharmaceutical company focused on precision medicines for serious oncology indications. Company news centers on NXP900, an oral small-molecule inhibitor of the SRC Family of Kinases, including SRC and YES1, and on clinical and preclinical work in genetically or molecularly defined cancer settings.
Recurring updates include financial results, business highlights, clinical program progress, AACR and other oncology conference presentations, pharmacokinetic and pharmacodynamic findings, drug-drug interaction data, and combination-therapy research in non-small cell lung cancer and other advanced solid tumors. News also covers capital resources and financing activity tied to development operations.
Nuvectis Pharma (NASDAQ: NVCT), a clinical-stage biopharmaceutical company developing precision oncology medicines for serious unmet medical needs, announced management participation in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ on Tuesday, May 19, 2026.
The company’s presentation, led by Chairman and CEO Ron Bentsur, is scheduled from 9:00–9:30 AM EDT in New York, NY. A live webcast will be accessible in the Investors section of the Nuvectis website.
Nuvectis Pharma (NASDAQ: NVCT) reported Q1 2026 results and clinical updates on May 5, 2026. Cash and cash equivalents were $25.1 million as of March 31, 2026, down from $31.6 million at year-end. Net loss was $6.1 million for Q1 2026. The NXP900 Phase 1b program continues to enroll in the US, with preclinical data presented at AACR showing synergy with sotorasib in NSCLC models. Management expects a preliminary Phase 1b data readout in summer 2026 and cited continued financial discipline while advancing clinical milestones.
Nuvectis Pharma (NASDAQ: NVCT) announced poster presentations for its clinical candidate NXP900 at the 2026 American Association for Cancer Research Meeting (AACR), April 17–22, 2026 in San Diego, CA.
Three abstracts will be presented April 21–22 covering synergy with KRAS inhibitors in NSCLC, resistance mechanisms in cholangiocarcinoma, and targeting MDSCs via SRC family kinase inhibition. Specific session times and titles are listed for each poster.
Nuvectis Pharma (NASDAQ: NVCT) reported 2025 results and program updates. Cash and cash equivalents were $31.6M at year-end, up from $18.5M in 2024, driven by a February 2025 public offering and ATM access. Net loss was $26.4M in 2025 versus $19.0M in 2024. Nuvectis said its Phase 1b monotherapy and osimertinib combination studies of NXP900 are enrolling, a lorlatinib combination is pending, and cash is expected to fund milestones into the second half of 2027.
Nuvectis Pharma (NASDAQ: NVCT) announced the initiation of a Phase 1b study of oral SRC/YES1 inhibitor NXP900 in combination with osimertinib (Tagrisso) for patients with EGFR-mutant non-small cell lung cancer (EGFRmut+ NSCLC) who initially responded to osimertinib and later acquired resistance.
The program follows a completed Phase 1a dose-escalation and a drug-drug interaction study; the single-agent Phase 1b study is ongoing. The company expects multiple clinical data readouts from single-agent and combination studies in 2026.
Nuvectis Pharma (NASDAQ: NVCT) will host a virtual Key Opinion Leader meeting on Tuesday, December 2, 2025 at 8:00 AM ET to discuss the NXP900 Phase 1b program in advanced solid tumors, including the combination with osimertinib in non-small cell lung cancer (NSCLC).
Speakers include Alexander Spira, MD, PhD, FACP, FASCO and Asier Uncita-Broceta, MPharm, MSc, PhD, who will join company management to review preclinical and clinical data to date, strategy for monotherapy and combination arms, and a live Q&A. A replay will be posted on the company's Investors page.
Nuvectis Pharma (NASDAQ: NVCT) reported Q3 2025 results and clinical updates on Nov 4, 2025. Key clinical milestones include initiation of the NXP900 Phase 1b single-agent study with combination dosing expected by year-end, completion of the Phase 1a dose-escalation showing robust pharmacodynamic responses, and a completed drug-drug interaction study supporting combination strategies. Poster presentations at the 2025 AACR-NCI-EORTC conference highlighted the emerging clinical profile and biomarker-based patient selection approach. Financially, cash and cash equivalents were $35.4M as of Sept 30, 2025, with a cash runway expected into 3Q-2027. Net loss was $7.5M in Q3 2025, up from $4.2M a year earlier.
Nuvectis Pharma (NASDAQ: NVCT) reported third-quarter 2025 results and operational updates on Nov. 4, 2025. Key clinical progress: NXP900 Phase 1b monotherapy component has commenced, the Phase 1a dose-escalation study completed with robust pharmacodynamic responses at clinically relevant once-daily doses, and a clinical drug-drug interaction study in healthy volunteers was completed supporting planned combination therapy. Poster presentations at the 2025 AACR-NCI-EORTC conference highlighted NXP900's emerging clinical profile and biomarker-based patient selection strategy. Financials: cash and cash equivalents $35.4M as of Sept 30, 2025 (vs $18.5M Dec 31, 2024), with cash runway expected into 3Q-2027. Q3 net loss was $7.5M, up from $4.2M year-ago, reflecting a $2.0M milestone and higher clinical costs.
Nuvectis Pharma (NASDAQ: NVCT) reported poster highlights for NXP900 presented at the 2025 AACR-NCI-EORTC conference. In a Phase 1a dose-escalation program (33 patients), NXP900 given once daily at 20–300 mg showed an acceptable safety profile with mostly Grade 1–2 diarrhea, fatigue and nausea, and elicited a robust pharmacodynamic response at doses ≥150 mg/day. A clinical drug-drug interaction study in healthy volunteers found no induction of key CYP450 enzymes. Preclinical FAT1‑mutant xenograft data showed tumor growth inhibition and YAP1 pathway suppression. The Phase 1b single‑agent study in tumors with YES1, FAT1, NF2 alterations is ongoing (NCT05873686); combination dosing is planned to start in the near term.
Nuvectis Pharma (NASDAQ: NVCT) announced poster presentations for its investigational candidate NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in Boston, MA, taking place October 22–26, 2025.
Two posters will appear in Poster Session A on October 23, 2025, 12:30–4:00 PM ET: LB-A019 covering clinical safety, pharmacokinetics, pharmacodynamics, and cytochrome P450 interactions (presenter Gerald Falchook, MD), and A099 reporting that NXP900 potently inhibits tumor growth in FAT1‑mutated xenograft models (presenter Asier Unciti‑Broceta).